Dermatology Focus Almirall specializes in medical dermatology with a portfolio spanning psoriasis, actinic keratosis, atopic dermatitis and acne, presenting strong cross-sell opportunities to dermatology clinics, hospitals and specialty distributors seeking targeted skin disease treatments.

Global Reach Operations in over 100 countries across five continents with 15 affiliates indicate a wide distribution network and multiple market entry points for partnerships, licensing, and regional co-development or commercialization deals.

R&D Momentum Active collaboration with Evotec on a dermatology-focused small molecule program and ongoing clinical and real-world evidence presentations signal a robust R&D pipeline and potential for alliance-based co-funding, technology licensing, and accelerated go-to-market strategies.

Regulatory Progress EMA acceptance for pediatric extension of Ebglyss (lebrikizumab) in atopic dermatitis demonstrates regulatory momentum and potential for expanded indication opportunities, enabling sales expansion into pediatric dermatology and associated payer conversations.

Financial Scale Revenue in the mid-range of hundreds of millions with external funding supports scalable investments in sales expansion, regional marketing pushes, and partnerships to grow market share against larger peers in the dermatology space.